博晖创新：关于控股子公司获得药物临床试验批准通知书的公告

Core Viewpoint - Beijing Bohui Innovation Biotechnology Group Co., Ltd. announced that its subsidiary, Guangdong Weirun Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of intravenous human immunoglobulin [1] Company Summary - The approval allows Guangdong Weirun Biopharmaceutical to commence clinical trials for its intravenous human immunoglobulin product [1]